Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients.

Cancer Immunol Immunother · 2025 · PMC12715060 · PMID 41410871

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although higher PTV and BED showed a trend towards worse PFS, neither were statistically significant, suggesting that the most predictive factor of progression was a change in NLR.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.